Feuerlein W, Heesch D, Schmidt L, Werner H P, Bethge H, Görtelmeyer R
Fortschr Med. 1984 Apr 12;102(14):409-13.
Liver damage is one of the most common organ manifestations of chronic alcoholism. The recovery process following abstinence should not be impaired by therapy with alcohol sensitizing drugs. In a double-blind multicentre-study (controlled against placebo) the liver tolerance of Nitrefazole which is indicated as an alcohol sensitizing agent for therapy of alcoholics, was tested during the first four weeks of a planned longterm therapy. A total of 62 patients with alcoholic liver disease--demonstrated clinically and in the laboratory--were tested. The patients received 800 mg of Nitrefazole (4 capsules a 200 mg), respectively 4 placebo capsules of identical appearance, once a week in the presence of the doctor. In both treatment groups there was a significant (p less than or equal to 0.01) decline of the previously pathologically altered laboratory values, especially concerning gamma-GT, GPT, GOT. The physical and mental condition which was additionally evaluated by the doctor improved within both treatment groups. The improvement of the liver functions due to abstinence is not delayed or impaired by Nitrefazole .
肝损伤是慢性酒精中毒最常见的器官表现之一。戒酒后的恢复过程不应因使用酒精增敏药物治疗而受到损害。在一项双盲多中心研究（与安慰剂对照）中，对一种被指定用于治疗酗酒者的酒精增敏剂硝呋唑在计划的长期治疗的前四周内的肝脏耐受性进行了测试。总共对62例经临床和实验室证实患有酒精性肝病的患者进行了测试。患者分别接受800毫克硝呋唑（4粒200毫克胶囊）或4粒外观相同的安慰剂胶囊，每周在医生在场的情况下服用一次。在两个治疗组中，先前病理改变的实验室值均有显著下降（p≤0.01），尤其是γ-谷氨酰转移酶、谷丙转氨酶、谷草转氨酶。医生额外评估的身体和精神状况在两个治疗组中均有所改善。硝呋唑不会延迟或损害因戒酒导致的肝功能改善。
